Overview
Frankfurt, August 27, 2025 –– McDermott Will & Schulte advised STADA Arzneimittel AG, based in Bad Vilbel, Germany, on the conclusion of a license agreement with China-based Bio-Thera Solutions covering the biosimilar Tocilizumab. The effectiveness of the agreement, which extends the biosimilars alliance between the two companies, is still subject to shareholder approval.
Tocilizumab an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. Bio-Thera will maintain responsibility for the development, manufacturing, and supply of the tocilizumab biosimilar to Roche’s RoActemra® reference brand. STADA will have exclusive rights to market the biosimilar in the EU, the UK, Switzerland, and selected other countries under its own authorization.
The agreement on tocilizumab builds on an existing partnership for BAT2506, a biosimilar candidate for Simponi® (golimumab), which STADA and Bio-Thera Solutions announced in May 2024. McDermott also acted as advisor to STADA in this initial agreement.
The McDermott team was led by partner Monika Richter and comprised partners Henrik Holzapfel, Margaret J. Sampson and Jana Grieb, as well as associate Katharina Hoffmeister.
About Us
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.
